Agios Pharmaceuticals Stock Slumps After Novo Nordisk Announces Superior Sickle Cell Drug
Agios Pharmaceuticals (AGIO) stock fell 26.8% following Novo Nordisk (NVO) announcing positive Phase 3 trial results for its sickle cell disease drug, etavopivat, which outperformed Agios' mitapivat. Novo's drug met both primary endpoints, while Agios' drug failed one. Agios is working with the FDA on mitapivat's regulatory pathway and may have another drug, tebapivat, in development for 2026.
Topics: drug competition FDA approval market competition pharmaceuticals stock price movement